Servier has become the first company to get US approval for an IDH inhibitor as a treatment for myelodysplastic syndromes (MDS) after its Tibsovo drug was cleared by the F
France’s Servier has become the latest pharma group to tap into an artificial intelligence platform for drug discovery, development, and diagnostics developed by Franco-US
Servier could become the first company to bring an IDH inhibitor to market in the US for patients with myelodysplastic syndromes (MDS) next year, after the FDA started a p
Servier’s vorasidenib has shown efficacy in the treatment of low-grade glioma – a notoriously hard-to-treat form of brain cancer – although safety data has taken some of t
AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovar
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio